CRISPR Therapeutics announced a leadership change with CFO Raju Prasad stepping down to pursue other opportunities. A.J. Silver, the company's Senior Vice President of Finance since 2025, will take over as CFO effective immediately. Silver brings extensive experience within the company and a strong background in finance, positioning him well to lead the finance team. This transition supports CRISPR Therapeutics' ongoing growth as a leader in gene-editing therapies.
As of Oct 20, 2026 03:11 WIB, CRISPR Therapeutics (CRSP) trades at USD 48.90, closer to its 52-week low of USD 44.34 than its high of USD 73.97, showing a modest 1-day decline of 0.71% on Pluang. Despite the recent CFO transition, the stock maintains strong buying interest with 83% of orders as buys and a typical hold time of 78 days, reflecting steady investor engagement in the health sector.
